Keyphrases
Psoriasis Vulgaris
100%
Biological Agents
100%
Drug Safety
100%
Drug Survival
100%
Confidence Interval
45%
Ustekinumab
36%
Infliximab
27%
Etanercept
27%
Loss of Effectiveness
27%
Adalimumab
27%
Survival Time
27%
Psoriasis
18%
Anti-tumor Necrosis Factor Agents
18%
Odds Ratio
18%
Kaplan-Meier Method
9%
Real-life Setting
9%
Biological Drugs
9%
Median Survival
9%
Observation Time
9%
Prospective Registry
9%
Real Patients
9%
Cox Regression
9%
Population Size
9%
Survival Rate
9%
Small Patients
9%
Large Cohort
9%
Patient Demographics
9%
Denmark
9%
Medical Needs
9%
Academic Center
9%
Pharmacology, Toxicology and Pharmaceutical Science
Biological Product
100%
Psoriasis Vulgaris
100%
Ustekinumab
80%
Etanercept
60%
Adalimumab
60%
Infliximab
60%
Median Survival Time
40%
Survival Time
40%
Psoriasis
40%
Tumor Necrosis Factor Inhibitor
40%
Survival Rate
20%
Immunology and Microbiology
Biological Product
100%
Ustekinumab
80%
Infliximab
60%
Adalimumab
60%
Etanercept
60%
Survival Time
40%
TNF Inhibitor
40%
Population Size
20%
Survival Rate
20%